WO2000021509A3 - Methods of treatment - Google Patents

Methods of treatment Download PDF

Info

Publication number
WO2000021509A3
WO2000021509A3 PCT/GB1999/003302 GB9903302W WO0021509A3 WO 2000021509 A3 WO2000021509 A3 WO 2000021509A3 GB 9903302 W GB9903302 W GB 9903302W WO 0021509 A3 WO0021509 A3 WO 0021509A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
inhibitor
receptor
receptor antagonist
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/003302
Other languages
French (fr)
Other versions
WO2000021509A2 (en
Inventor
Stefan Dietmar Anker
Andrew Justin Stewart Coats
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9822459.5A external-priority patent/GB9822459D0/en
Priority claimed from GBGB9822458.7A external-priority patent/GB9822458D0/en
Priority claimed from GBGB9917181.1A external-priority patent/GB9917181D0/en
Priority to AT99947762T priority Critical patent/ATE457169T1/en
Priority to US09/807,558 priority patent/US7417038B1/en
Priority to JP2000575485A priority patent/JP2002527378A/en
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to EP99947762A priority patent/EP1121111B1/en
Priority to DE69942009T priority patent/DE69942009D1/en
Priority to DK99947762.3T priority patent/DK1121111T3/en
Publication of WO2000021509A2 publication Critical patent/WO2000021509A2/en
Publication of WO2000021509A3 publication Critical patent/WO2000021509A3/en
Anticipated expiration legal-status Critical
Priority to US12/192,780 priority patent/US7829596B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)

Abstract

A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antogonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia.
PCT/GB1999/003302 1998-10-15 1999-10-15 Methods of treatment Ceased WO2000021509A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK99947762.3T DK1121111T3 (en) 1998-10-15 1999-10-15 Compounds for the treatment of weight loss
DE69942009T DE69942009D1 (en) 1998-10-15 1999-10-15 CONNECTIONS FOR THE TREATMENT OF WEIGHT LOSS
EP99947762A EP1121111B1 (en) 1998-10-15 1999-10-15 Compounds for the treatment of weight loss
US09/807,558 US7417038B1 (en) 1998-10-15 1999-10-15 Methods of treating cachexia
JP2000575485A JP2002527378A (en) 1998-10-15 1999-10-15 Method of treatment
AT99947762T ATE457169T1 (en) 1998-10-15 1999-10-15 COMPOUNDS FOR THE TREATMENT OF WEIGHT LOSS
US12/192,780 US7829596B2 (en) 1998-10-15 2008-08-15 Methods of treatment

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9822459.5A GB9822459D0 (en) 1998-10-15 1998-10-15 Method of treatment
GBGB9822458.7A GB9822458D0 (en) 1998-10-15 1998-10-15 Methods of treatment
GB9917181.1 1999-07-23
GB9822458.7 1999-07-23
GBGB9917181.1A GB9917181D0 (en) 1999-07-23 1999-07-23 Methods of treatment
GB9822459.5 1999-07-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/807,558 A-371-Of-International US7417038B1 (en) 1998-10-15 1999-10-15 Methods of treating cachexia
US12/192,780 Division US7829596B2 (en) 1998-10-15 2008-08-15 Methods of treatment

Publications (2)

Publication Number Publication Date
WO2000021509A2 WO2000021509A2 (en) 2000-04-20
WO2000021509A3 true WO2000021509A3 (en) 2000-11-09

Family

ID=27269516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/003302 Ceased WO2000021509A2 (en) 1998-10-15 1999-10-15 Methods of treatment

Country Status (9)

Country Link
US (2) US7417038B1 (en)
EP (1) EP1121111B1 (en)
JP (1) JP2002527378A (en)
AT (1) ATE457169T1 (en)
CY (1) CY1110282T1 (en)
DE (1) DE69942009D1 (en)
DK (1) DK1121111T3 (en)
PT (1) PT1121111E (en)
WO (1) WO2000021509A2 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942009D1 (en) * 1998-10-15 2010-03-25 Imp Innovations Ltd CONNECTIONS FOR THE TREATMENT OF WEIGHT LOSS
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7794987B2 (en) 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1784390A2 (en) 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
DK1814590T4 (en) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Treatment of obesity and related diseases.
CA2646131C (en) * 2005-03-21 2018-09-04 Vicus Therapeutics Spe 1, Llc Compositions and methods for ameliorating cachexia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDONE COMPOUND
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
KR20080048502A (en) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2008119687A (en) 2005-10-21 2009-11-27 Новартис АГ (CH) COMBINATIONS OF ORGANIC COMPOUNDS
IE20050723A1 (en) * 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
EA019757B1 (en) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Pharmaceutical composition with synergistic anticonvulsant effect
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLCETTIMINE DERIVATIVE
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
CA2717384A1 (en) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
ES2627848T3 (en) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009257174A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
RU2392933C2 (en) * 2008-07-18 2010-06-27 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) Hypolipidemic agent
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
CA2732513C (en) 2008-08-01 2017-04-25 Arca Biopharma, Inc. Methods and compositions involving (s)-bucindolol
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
GB0907350D0 (en) 2009-04-29 2009-06-10 Myotec Therapeutics Ltd Methods
EP2523731B1 (en) 2010-01-14 2018-10-24 Novartis AG Use of an adrenal hormone-modifying agent
MX2012009318A (en) 2010-02-10 2012-09-07 Novartis Ag Methods and compounds for muscle growth.
JP2013520502A (en) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション Novel cyclic benzimidazole derivatives that are useful anti-diabetic drugs
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
KR20130074808A (en) * 2011-12-16 2013-07-05 한올바이오파마주식회사 The pharmaceutical composition comprising losartan for treating or preventing statin-induced muscle toxicity
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (en) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic bicyclic compound
HRP20182041T1 (en) 2013-03-14 2019-02-08 Actimed Therapeutics Ltd OXPRENOLOL PREPARATIONS FOR CANCER TREATMENT
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PL3004138T3 (en) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112017003745A2 (en) 2014-08-29 2017-12-05 Tes Pharma S R L alpha-amino-beta-carboximuconic acid semialdehyde decarboxylase inhibitors
US11096908B2 (en) 2016-02-26 2021-08-24 Actimed Therapeutics Ltd S-enantiomerically enriched compositions of beta blockers for treating muscle weakness
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
EP3883930A1 (en) 2018-11-20 2021-09-29 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same
GB2593902B (en) 2020-04-07 2022-04-13 Actimed Therapeutics Ltd Salt of a pharmaceutical compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024373A2 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist
JPH0971586A (en) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd Novel bicyclic fused imidazole derivative

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541188A (en) 1987-09-15 1996-07-30 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
US6545040B1 (en) 1988-03-23 2003-04-08 Janssen Pharmaceutica N.V. Method of lowering the blood pressure
AU643487B2 (en) * 1989-11-21 1993-11-18 Sepracor, Inc. Use of optically pure s(-) atenolol for the treatment of cardiovascular disorders
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of a drug by a serotonin 1A receptor antagonist
AUPO274596A0 (en) 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
GB9714675D0 (en) 1997-07-11 1997-09-17 Smithkline Beecham Plc Novel composition
DE69942009D1 (en) 1998-10-15 2010-03-25 Imp Innovations Ltd CONNECTIONS FOR THE TREATMENT OF WEIGHT LOSS
HUP0204262A2 (en) 2000-01-31 2003-04-28 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes and pharmaceutical compositions containing the compounds
WO2003065970A2 (en) 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
WO2006030306A2 (en) 2004-09-17 2006-03-23 Neurocure Ltd Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
US20060069086A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2646131C (en) 2005-03-21 2018-09-04 Vicus Therapeutics Spe 1, Llc Compositions and methods for ameliorating cachexia
MX2008007790A (en) 2005-12-22 2009-03-04 Anaborex Inc Compositions and methods for prevention and treatment of cachexia.
WO2007100775A2 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CL2007003227A1 (en) 2006-11-09 2008-07-04 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES A BENEFIT DERIVATIVE REPLACED WITH GLUCOPIRANOSIL IN COMBINATION WITH ONE OR MORE THERAPEUTIC AGENTS; AND USE FOR THE TREATMENT OF MELLITUS DIABETES, OBESITY AND HYPERGLUCEMIA BETWEEN OTHERS.
KR101546977B1 (en) 2007-04-24 2015-08-24 아카시아 파마 리미티드 Drug combinations in the treatment of muscle loss and its uses
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024373A2 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist
JPH0971586A (en) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd Novel bicyclic fused imidazole derivative

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANKER S D ET AL: "Insights into the pathogenesis of chronic heart failure: immune activation and cachexia.", CURRENT OPINION IN CARDIOLOGY, (1999 MAY) 14 (3) 211-6. REF: 62, XP000892578 *
DANERYD P ET AL: "Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study.", CANCER RESEARCH, (1998 DEC 1) 58 (23) 5374-9., XP000877491 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; HUANG ZHENWEN, LIU RUIYUN ET AL: "Antialdosterone therapy in severe chronic congestive heart failure.", XP002137362, retrieved from STN *
DATABASE WPI Derwent World Patents Index; AN 1997-231178, XP002137363, "New bi-cyclic fuse imidazole derivatives used as aldosterone byosinthesis inhibitors, e.g. for treting chronic or congestive heart failure" *
GAGNON B ET AL: "A review of the drug treatment of cachexia associated with cancer.", DRUGS, (1998 MAY) 55 (5) 675-88. REF: 136, XP000892586 *
GORTER R: "MANAGEMENT OF ANOREXIA-CACHEXIA ASSOCIATED WITH CANCER AND HIV INFECTION", ONCOLOGY,CH,S. KARGER AG, BASEL, vol. 5, no. 9, 1 September 1991 (1991-09-01), pages 13 - 17, XP002054943, ISSN: 0030-2414 *
GREENBAUM L M ET AL: "Host cathepsin D response to tumor in the normal and pepstatin-treated mouse.", CANCER RESEARCH, (1983 JUN) 43 (6) 2584-7., 1983, XP000892417 *
LEZA J.C. ET AL: "Buprenorphine suppresses weight loss and abstinence in morphine-dependent mice.", REVISTA DE FARMACOLOGIA CLINICA Y EXPERIMENTAL, (1987) 4/4 (377-383)., XP000892647 *
ZHONGHUA XINXUEGUANBING ZAZHI, (1996) VOL. 24, NO. 1, PP. 12-15. *

Also Published As

Publication number Publication date
US20090023639A1 (en) 2009-01-22
DE69942009D1 (en) 2010-03-25
US7829596B2 (en) 2010-11-09
PT1121111E (en) 2010-05-17
ATE457169T1 (en) 2010-02-15
US7417038B1 (en) 2008-08-26
CY1110282T1 (en) 2015-01-14
WO2000021509A2 (en) 2000-04-20
EP1121111A2 (en) 2001-08-08
EP1121111B1 (en) 2010-02-10
DK1121111T3 (en) 2010-05-31
JP2002527378A (en) 2002-08-27

Similar Documents

Publication Publication Date Title
CY1110282T1 (en) UNIONS FOR THE WEIGHT LOSS TREATMENT
WO2004017941A3 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
EP1059100A3 (en) Combinations of CRF antagonists and renin-angiotensin system inhibitors
WO2004108157A8 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
WO2003070191A8 (en) Tamper-resistant transdermal opioid delivery devices
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2000040227A3 (en) Methods for treating conditions associated with the accumulation of excess extracellular matrix
HK1044333A1 (en) Chemokine receptor antagonists and methods of use therefor
WO2002013801A3 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
WO1998036061A3 (en) Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
WO2000064474A8 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
WO2003045434A3 (en) Endothelin antagonists ina method and composition for potentiating an opiate analgesic
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
IS4847A (en) Method for the treatment of heart failure using endothelin antagonists
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
WO2001009119A3 (en) Chemokine receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999947762

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 575485

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09807558

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999947762

Country of ref document: EP